Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus and diphtheria toxoids adsorbed
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Tetanus and diphtheria toxoids adsorbed is a fixed-combination vaccine containing inactivated (toxoid) forms of the toxins produced by *Clostridium tetani* (tetanus) and *Corynebacterium diphtheriae* (diphtheria), which are adsorbed onto an aluminum adjuvant to enhance immune response. The vaccine is indicated for active immunization against both diseases. It works by stimulating the body’s immune system to produce antibodies that protect against future infections with these bacteria. There are two main formulations: DT (for children under 7 years old) contains a higher dose of diphtheria toxoid; Td (for individuals 7 years or older) contains a lower dose of diphtheria toxoid[1][3][4][5]. The primary indication is prevention of tetanus ("lockjaw") and diphtheria through routine childhood vaccination or booster doses in adults[2][4].
- Brand names
- TenivacTd Adsorbed
- Other names
- diphtheria and tetanus toxoids adsorbedDT vaccineTd vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on tetanus and diphtheria toxoids adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus and diphtheria toxoids adsorbed.